Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 672

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 4
Chunk 672
---
 price of outstanding stock options as of December 31, 2024:

 SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS 

    Exercise price 
    Options  outstanding 

    $0.01 - $8.00 
     1,861,499 

    $0.01 - $8.00 
     1,861,499 
  
    $8.01 - $16.00 
     992,250 
  
    $16.01 or higher 
     34,073 
  
    Total 
     2,887,822 

NOTE
6: CAPITALIZATION

    a.
    As
    of December 31, 2024 and December 31, 2023, the Company had 200,000,000
    shares of common stock authorized and 12,013,901
    and 8,401,047
    shares issued and outstanding, respectively. As of December 31, 2024 and December 31, 2023, the Company had 5,000,000
    shares of preferred stock authorized. There were no shares of preferred stock issued or outstanding as of December 31, 2024 and
    2023. As of December 31, 2024 and December 31, 2023, there were warrants outstanding to purchase an aggregate of 6,675,853
    and 3,090,787
    shares of common stock, respectively. As of December 31, 2024, these warrants are exercisable at a weighted average price of $6.52
    and their weighted average remaining contractual term is 3.5
    years.

    F-12

    b.
    On June 1, 2022, the Company
    entered into an At The Market Offering Agreement (the “ATM Agreement”) which was amended on September 1, 2022 with a
    sales agent, pursuant to which the Company may offer and sell, from time to time through the sales agent, shares of the Company’s
    common stock, par value $0.01 per share. The issuance and sale of common stock by the Company under the ATM
    Agreement is being made pursuant to the Company’s effective “shelf” registration statement on Form S-3 filed
    with the SEC on September 1, 2022 and declared effective on September 9, 2022. In 2024